Department of Urology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Department of Medical Chemistry and Clinical Biochemistry, Motol University Hospital, 2 Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Anticancer Res. 2023 Apr;43(4):1675-1680. doi: 10.21873/anticanres.16319.
BACKGROUND/AIM: Serum thymidine kinase 1 (STK1) is a proliferation biomarker that has been used as a diagnostic marker of several malignant diseases. However, there are limited data for prostate cancer (PCa).
In this study, we retrospectively analysed serum samples from 169 patients with biopsy confirmed PCa, who had been indicated for radical prostatectomy (RP) between 2013-2016. The results were compared with those in serum samples from 39 healthy men. We used commercially available enzymatic immunoassay to determine the levels of STK1. The patients were divided into groups according to the Gleason score (GS) and risk factors for adjuvant radiotherapy (aRT), which were defined as GS 8-10, pT3, and a positive surgical margin.
The median serum level of STK1 in PCa patients was 0.289 pmol/l. In the control group, the median value was 0.0116 pmol/l (p<0.001). By comparing the patients with GS≤6 vs. 7 vs. ≥8 (p=0.01), we found statistically significant differences. In the correlation of STK1 values with risk factors, we found statistically significant differences both in comparison of 0 vs. 1 vs. 2 vs. 3 risk factors (p=0.021), as well as ≤1 vs. 2≥ risk factors (p=0.009).
The levels of STK1 are significantly higher in patients with PCa than those in healthy controls. Furthermore, STK1 values correlate with GS and predefined risk factors for aRT. Therefore, STK1 can be considered as a potential tumour marker of PCa diagnosis and risk stratification.
背景/目的：血清胸苷激酶 1（STK1）是一种增殖生物标志物，已被用作几种恶性疾病的诊断标志物。然而，关于前列腺癌（PCa）的数据有限。
在这项研究中，我们回顾性分析了 2013-2016 年间因根治性前列腺切除术（RP）而接受活检证实的 169 例 PCa 患者的血清样本。结果与 39 名健康男性的血清样本进行了比较。我们使用商业上可获得的酶免疫测定法来确定 STK1 的水平。根据 Gleason 评分（GS）和辅助放疗（aRT）的危险因素，将患者分为 GS 8-10、pT3 和阳性手术切缘的组。
PCa 患者的血清 STK1 中位数水平为 0.289 pmol/l。对照组的中位数为 0.0116 pmol/l（p<0.001）。通过比较 GS≤6 与 7 与≥8 的患者（p=0.01），我们发现存在统计学差异。在 STK1 值与危险因素的相关性中，我们发现 0 与 1 与 2 与 3 个危险因素（p=0.021）以及≤1 与≥2 个危险因素（p=0.009）之间存在统计学差异。
PCa 患者的 STK1 水平明显高于健康对照组。此外，STK1 值与 GS 和预定的 aRT 危险因素相关。因此，STK1 可被视为 PCa 诊断和风险分层的潜在肿瘤标志物。
